Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Ratios of sFlt-1 to P1GF or endoglin to P1GF as biomarkers for preeclampsia related adverse outcomes after birth

Ratios of sFlt-1 to P1GF or endoglin to P1GF as biomarkers for preeclampsia related adverse outcomes after birth

US Patent 12105096 · Granted Oct 1, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Dynamic of sFlt-1 or endoglin/PIGF ratio as an indicator for imminent preeclamps2025
Biomarkers for risk assessment and treatment monitoring in heart failure patient2024
Means and methods applying sFlt-1/PlGF or endoglin/PlGF ratio to rule out onset 2024
IGFBP-7 as a marker of preeclampsia2024
Marker for statin treatment stratification in heart failure2022
IGFBP7 for diagnosing diastolic dysfunction2021
Biomarkers for risk assessment and treatment monitoring in heart failure patient2020
Biomarkers for risk prediction of mortality2020
Method for setting up a local control channel between a control unit and a build2019
Controlling communication between a building-external communication server and a2019
IGFBP7 for diagnosing diastolic dysfunction2019
Dynamic of sFlt-1 or endoglin/PLGF ratio as an indicator for imminent preeclamps2019